[Ulipristal in uterine myomatosis]
Mengarelli C, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001423
Spanish
Original Title:
Ulipristal en miomatosis uterina
Authors' recommendations:
CONCLUSIONS
High-quality evidence suggests that the use of ulipristal acetate in women of childbearing potential with symptomatic uterine myomatosis would be more effective and safer than gonadotropin-releasing hormone analogues in controlling moderate and severe metrorrhagias and reducing the tumor size at short term. No studies assessing a reduction in the rates of myomectomy or hysterectomy have been found.
The clinical practice guidelines from Latin America, Europe and Canada consider ulipristal as a valid alternative to gonadotropin-releasing hormone analogues in women of childbearing potential with severe metrorrhagia, symptomatic anemia, more than 3-cm-myomas and the need for uterus preservation.
Most European health sponsors cover this treatment. It is not covered by the United States health sponsors because it is not approved by the American regulatory agency for this indication. No health policies have been found in Latin America.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Uterine Neoplasms
- Leiomyoma
- Progesterone
- Norpregnadienes
- Drug Therapy
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.